Liquidia (NASDAQ:LQDA) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Liquidia (NASDAQ:LQDA) to a strong-buy rating in a report released on Thursday,Zacks.com reports.

Other equities analysts have also issued research reports about the stock. Jefferies Financial Group increased their target price on shares of Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, January 13th. Wells Fargo & Company boosted their price target on shares of Liquidia from $31.00 to $44.00 and gave the stock an “overweight” rating in a research report on Friday. Needham & Company LLC upped their price target on shares of Liquidia from $52.00 to $54.00 and gave the stock a “buy” rating in a research note on Thursday. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a report on Thursday. Finally, Wall Street Zen upgraded shares of Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Liquidia Trading Up 4.4%

NASDAQ:LQDA opened at $36.03 on Thursday. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. Liquidia has a 52 week low of $11.26 and a 52 week high of $46.67. The business’s 50 day moving average is $37.10 and its two-hundred day moving average is $30.92. The company has a market cap of $3.13 billion, a PE ratio of -43.41, a P/E/G ratio of 0.62 and a beta of 0.52.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.18). Liquidia had a negative return on equity of 237.79% and a negative net margin of 43.53%.The business had revenue of $92.02 million during the quarter. The firm’s revenue was up 3072.4% on a year-over-year basis. On average, analysts predict that Liquidia will post -1.51 EPS for the current year.

Insider Buying and Selling at Liquidia

In other news, insider Rajeev Saggar sold 21,142 shares of the company’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $37.43, for a total transaction of $791,345.06. Following the completion of the sale, the insider directly owned 176,883 shares of the company’s stock, valued at $6,620,730.69. This represents a 10.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Dana Boyle sold 1,580 shares of the stock in a transaction on Monday, January 26th. The shares were sold at an average price of $41.65, for a total value of $65,807.00. Following the completion of the transaction, the chief accounting officer owned 178,848 shares of the company’s stock, valued at $7,449,019.20. This trade represents a 0.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 212,534 shares of company stock worth $7,964,719. 26.50% of the stock is owned by insiders.

Institutional Trading of Liquidia

Several institutional investors and hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Liquidia by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock worth $556,000 after buying an additional 1,700 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Liquidia by 10.7% during the first quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after acquiring an additional 82,955 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Liquidia by 15.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after acquiring an additional 16,022 shares during the period. Teacher Retirement System of Texas lifted its position in shares of Liquidia by 25.4% in the 2nd quarter. Teacher Retirement System of Texas now owns 17,185 shares of the company’s stock valued at $214,000 after acquiring an additional 3,478 shares in the last quarter. Finally, Tyro Capital Management LLC acquired a new position in Liquidia in the 2nd quarter worth approximately $15,473,000. Institutional investors and hedge funds own 64.54% of the company’s stock.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Commercial momentum and profitability — Liquidia reported YUTREPIA net product sales of $90.1M in Q4 and $148.3M for 2025, achieved a second consecutive profitable quarter (Q4 net income $14.6M) and positive adjusted EBITDA, signaling rapid launch adoption and improving unit economics. GlobeNewswire Release
• Positive Sentiment: Balance sheet strength — the company ended 2025 with ~$190.7M in cash, improving liquidity and backing management’s plan to fund commercial expansion and clinical programs from operations. Quiver Quant Summary
• Positive Sentiment: Analyst upgrades and higher price targets — several firms raised ratings/targets after the quarter (HC Wainwright to $55, Needham to $54, BTIG to $50, Wells Fargo to $44), which supports further upside and likely contributed to intraday buying. Benzinga Analyst Roundup
• Neutral Sentiment: Mixed EPS headlines — Liquidia reported GAAP EPS of $0.15 for Q4. That missed some sell‑side consensus figures (~$0.33) but beat other estimates (Zacks cited $0.08), creating mixed investor interpretation of the results. Zacks Coverage
• Neutral Sentiment: Earnings materials and management commentary available — the slide deck and transcript provide color on commercial adoption, prescriber metrics and plans to fund L606 and other programs; useful for assessing sustainability of the launch. Earnings Presentation (Seeking Alpha)
• Negative Sentiment: Initial market reaction to the EPS headline — shares gapped down on the earnings headline before rebounding, showing sensitivity to EPS versus revenue/profitability nuance. That initial gap indicates headline risk if future quarters miss expectations. DefenseWorld: Gap Down
• Negative Sentiment: Insider and institutional sales — recent filings and summaries show notable insider sell activity and some large institutional reductions, which can weigh on sentiment if sustained. Fool: SEC Filing

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).